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European Journal of Cardio-thoracic Surgery 38 (2010) 239—240The 23rd Annual Meeting of the European Association for
Cardio-Thoracic Surgery to be held in Geneva, September
11—14, 2010 (www.eacts.org) is the event to find out all
about what is NEXT, i.e. New Events in Xurgical Technology. As
everyone knows surgery has its origin in the Greek term
xeiroyrgikZ (cheirourgike¯) which means ‘hand work’.
Further enhancement of what can be done manually requires
instruments or, in other words, technology. In addition,
problems with technology are usually approached with more
technology. As a matter of fact, cardiac, thoracic and
vascular surgeries are very technology driven fields and there
are a numerous examples in this volume of the European
Journal of Cardio-Thoracic Journal [1—7], etc.).
One key issue is of course how to get from a good idea for a
new surgical device [6] to an approved implant or instrument
which can be used in routine fashion for the clinical practice?
There have been two interesting papers in the recent issues
of the European Journal for Cardio-Thoracic Surgery by Vecht
et al. showing first, how to protect one’s assets by securing
the intellectual property [8], and second how typical
pathways for prototyping, certification, manufacturing,
marketing, and financing [9] can look like.
Basically, there are two concepts for financial engineering
around the creation of a start-up company for the NEXT
product. Either the ‘self-financed’ route which may involve
the family and friends versus the totally ‘venture capital
financed’ route.
The venture capital financed route requires a good story
and a lot of effort to convince the fund managers. It may
allow for attracting big investments, which in conjunction
with a brilliant team can shorten the time to market by
parallel processing, and a global roll-out. It can potentially
generate huge returns. The main price for this strategy is,
that the inventor is usually removed from the commands
early on, his holdings are diluted accordingly or vice versa,
and the initial spirit of the invention may be completely lost.
Hence, it is of prime importance for the inventor to negotiate
adequate rewards for his contributions from the very
beginning.
In contrast, the self-financed route is an extremely
tedious one. Most of the problems occurring at the various
levels of development, certification, production, marketing
and sales have to be solved typically by the few persons in§ Conflict of interest: LKvS is founder and shareholder of Smartcanula LLC,
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are usually short of cash, which provides the necessary
pressure to find efficient solutions (positive), but big jumps
are just out of question (negative). Potential suppliers as
well as customers have to be convinced almost one by one,
which in turn slows down the penetration of the markets
even if an innovative well functioning product can be made
available readily. Hence, the financial compensations early
on are none or insignificant as compared to a well negotiated
deal for the scenario outlined above, but, it is possible
to stay in control of the entire operation for the time it
takes, and thus after all the final reward may turn out to be
superior.
Of course there are all sorts of combinations in-between
these two scenarios, but not all products are suitable for
both. Typically, the development, production, and marketing
of an artificial heart [10] or even a prosthetic heart valve [11]
can rarely be financed out of one single pocket, and in order
to get somewhere, multiple rounds of investments by
organizations willing to take some risks are unavoidable. In
contrast, it is still possible for relatively simple devices [12],
to evolve under the inventor’s direction at a much smaller
scale, and of course, slower pace. In the latter case limited
funding from start-up friendly foundations and government
agencies which do not have too many strings attached can be
of major help for scientific proof of principle (e.g. Swiss
National Science Foundation: www.snf.ch, and the equiva-
lents in other countries) or processing clearly defined work
packages for industrialization (e.g. Swiss confederation
innovation promotion agency: www.CTIstartup.ch, and the
equivalents in other countries).
The emerging discipline of Venture Philanthropy provides
a promising third option along with self-funding and
traditional venture capital investment. Not-for-profit orga-
nizations can put their considerable resources into play, in
ways consistent with their mission, at a time in product
development that is too early for traditional venture
investment and too late for academic funding. While such
organizations invest instead of giving grants, they do so with
an eye toward re-distributing profits to evergreen funds to
use for future investments always within their philanthropic
goals. In this way they help to bridge the so-called translation
gap, the transition in product development between bench
and bedside where financing is known to be difficult. In
cardio-vascular disease, Broadview Ventures (www.broad-
viewventures.org) has been established by the trust thatSurgery. Published by Elsevier B.V. All rights reserved.
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this problem. With a mission to accelerate the development
of technology in diagnosis and treatment of cardio-vascular
and neuro-vascular diseases through targeted investments,
Broadview aims to make resources available to inventors and
early stage companies to help to insure that promising
technology can move forward. Ultimately, this is in every-
one’s interest.
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